Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Stavros Gkolfinopoulos, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6720.

https://doi.org/10.1182/blood-2023-173072

Published: 2023

Journal Articles

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Panagiotis Zis, Rodanthi Syrigou, Stella Fanouraki, Maria Gavriatopoulou, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 529.

https://doi.org/10.1182/blood-2023-180673

Published: 2023

Journal Articles

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

Blood (2023) 142 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2023-181029

Published: 2023

Journal Articles

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Evangelos Terpos, Efstathios Kastritis, Argiris Symeonidis, Anastasia Pouli, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2023-173185

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Giorgos Psarros, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2023-173064

Published: 2023

Journal Articles

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Konstantinos Soureas, Christos Minopoulos, Maria-Alexandra Papadimitriou, Panagiotis Malandrakis, Panagiotis Adamopoulos, Ioannis Ntanasis-Stathopoulos, Aristea-Maria Papanota, Maria Gavriatopoulou, Diamantis C Sideris, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris

Blood (2023) 142 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2023-186495

Published: 2023

Journal Articles

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Evangelos Eleutherakis-Papaiakovou, Chrysanthi Panteli, Panagiotis Malandrakis, Nikolaos Angelis, Nikolaos Kanellias, Georgia Dimitrakopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 880.

https://doi.org/10.1182/blood-2023-186259

Published: 2023

Journal Articles

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Blood (2023) 142 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2023-179416

Published: 2023

Journal Articles

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Blood (2023) 142 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2023-173074

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

Journal Articles

Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center

Efstathios Kastritis, Foteini Theodorakakou, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 4279–4280.

https://doi.org/10.1182/blood-2022-166185

Published: 2022

Journal Articles

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 4275–4276.

https://doi.org/10.1182/blood-2022-165403

Published: 2022

Journal Articles

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Sandra Basic - Kinda, Roman Hajek, Ankit Pahwa, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy A. Ross, Carlos Hader

Blood (2022) 140 (Supplement 1): 12481–12482.

https://doi.org/10.1182/blood-2022-159677

Published: 2022

Journal Articles

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7267–7268.

https://doi.org/10.1182/blood-2022-162208

Published: 2022

Journal Articles

The Cancer-Related Circrna Cirs-7 ( CDR1-AS ) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma

Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis-Stathopoulos, Paraskevi Karousi, Panagiotis Malandrakis, Foteini Theodorakakou, Christine Ivy Liacos, Aikaterini-Anna Liosi, Maria-Anna Kalioraki, Nefeli Mavrianou-Koutsoukou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 7239–7240.

https://doi.org/10.1182/blood-2022-169779

Published: 2022

Journal Articles

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

Ioannis V Kostopoulos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Pantelis Roussakis, Evangelos Eleutherakis Papaiakovou, Chrysanthi Panteli, Nikolaos Angelis, Nikolaos Kanellias, Nikolaos Orologas-Stavrou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 1564–1565.

https://doi.org/10.1182/blood-2022-162689

Published: 2022

Journal Articles

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Efstathios Kastritis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Eirini Solia, Panagiotis Malandrakis, Rodanthi Syrigou, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7324–7325.

https://doi.org/10.1182/blood-2022-165792

Published: 2022

NARROW

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

The Cancer-Related Circrna Cirs-7 ( CDR1-AS ) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only